bintrafusp alfa (M7824) / EMD Serono  >>  Phase 2
Welcome,         Profile    Billing    Logout  

47 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bintrafusp alfa (M7824) / EMD Serono
NCT03707587: M7824 in People With Recurrent Respiratory Papillomatosis

Completed
2
9
US
M7824
National Cancer Institute (NCI)
Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis, Laryngeal Papilloma, Recurrent, Human Papilloma Virus
10/19
07/22
2019-004052-11: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma

Not yet recruiting
2
59
Europe
Bintrafusp alfa, M7824, Concentrate for solution for infusion
UNICANCER, Merck Healthcare KGaA
Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a diagnosis of head and neck squamous cell carcinoma (HNSCC) from unknown primary will not be enrolled., -, Diseases [C] - Cancer [C04]
 
 
2020-002079-36: Feasability study for treatment with definitive chemoradiotherapy and bintrafusp alfa for patients with esophageal cancer (TAPESTRY) Haalbaarheidsonderzoek naar de behandeling van definitieve chemoradiotherapie en bintrafusp alfa bij patiënten met slokdarmkanker (TAPESTRY)

Not yet recruiting
2
52
Europe
bintrafusp alfa, Paclitaxel, Carboplatin, Concentrate for solution for infusion, Concentrate for solution for injection/infusion, Paclitaxel, Carboplatin
Amsterdam University Medical Centers, Amsterdam University Medical Centers
Esophageal squamous cell carcinoma Plaveiselcelcarcinoom van de oesofagus, esophageal cancer slokdarmkanker, Diseases [C] - Cancer [C04]
 
 
MS200647_0047, NCT03833661 / 2018-003707-19: M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Checkmark Data from trial for 2L biliary tract cancer
Mar 2021 - Mar 2021: Data from trial for 2L biliary tract cancer
Completed
2
159
Europe, Japan, US, RoW
M7824, Bintrafusp alfa
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
11/20
09/22
NCT04501094: A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Terminated
2
2
US
Bintrafusp alfa (M7824), M7824
National Cancer Institute (NCI)
Urothelial Cancer
01/21
10/21
18-C-0056, NCT03427411: M7824 in Subjects With HPV Associated Malignancies

Completed
2
57
US
M7824, MSB0011359C
National Cancer Institute (NCI)
Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vaginal or Penile Cancer
02/21
12/22
NCT04560686: Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer

Terminated
2
2
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Resectable Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
07/21
07/21
2020-005703-39: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Bintrafusp alfa et doxorubicine chez les patients traités pour un sarcome avancé.

Not yet recruiting
2
80
Europe
Bintrafusp alfa, DOXORUBICIN, M7824, Concentrate for solution for injection/infusion, Solution for infusion, DOXORUBICIN
Institut Bergonié, Merck Healthcare KGaA
soft-tissue sarcoma sarcomes des tissus mous, soft-tissue sarcoma sarcomes des tissus mous, Diseases [C] - Cancer [C04]
 
 
ICING, NCT04428047: Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma

Terminated
2
7
Europe
bintrafusp alfa, M7824
UNICANCER, Merck KGaA, Darmstadt, Germany
Squamous Cell Carcinoma of Head and Neck
09/21
01/22
NEOBIL, NCT04727541: Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

Terminated
2
3
Europe
Bintrafusp alfa, MSB0011359C, M7824
AIO-Studien-gGmbH, Merck Serono GmbH, Germany
Biliary Tract Cancer, Cholangiocarcinoma
10/21
01/22
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II.

Not yet recruiting
2
66
Europe
Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide)
Institut Bergonié, Incyte Biosciences International Sarl
retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04]
 
 
2020-002605-25: Neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer (NEOBIL) Neoadjuvante Therapie mit Bintrafusp alfa bei Patienten mit operablem Krebs der Gallenwege

Not yet recruiting
2
24
Europe
Bintrafusp Alfa, MSB0011359C, Infusion
AIO-Studien-gGmbH, Merck Healthcare KGaA
Treatment-naive subjects with a diagnosis of resectable biliary tract cancer, confirmed by histopathology Behandlungsnaive Patienten mit histologisch diagnostiziertem operablen Gallengangskarzinom, Subjects with a diagnosis of resectable biliary tract cancer, confirmed by histopathology Patienten mit der Diagnose eines operablem Gallengangkrebs, Diseases [C] - Cancer [C04]
 
 
MS200647_0020, NCT04489940 / 2019-004833-18: Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Hourglass Jan 2023 - Mar 2023 : Data from trial for TNBC
Terminated
2
11
Europe, US, RoW
Bintrafusp alfa, M7824
EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Triple Negative Breast Neoplasms
01/22
07/22
NCT04971187: Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Terminated
2
3
US
Bintrafusp Alfa, 1918149-01-5, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Pemetrexed, 137281-23-3, L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), MTA, Multitargeted Antifolate, Pemfexy, Carboplatin, (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O'']platinum, 1-cyclobutanedicarboxylic acid platinum complex, 41575-94-4, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum, cis-diammine(cyclobutanedicarboxylato)platinum II, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, Platinwas, Ribocarbo, Cisplatin, (SP-4-2)-Diamminedichloroplatinum, 15663-27-1, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Diaminedichloro-, cis- (8CI), Platiran, Platistin, Platosin
M.D. Anderson Cancer Center
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
02/22
02/22
MS200647_0017, NCT04246489 / 2019-003583-40: Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Hourglass Apr 2022 - Jun 2022 : Data from INTR@PID 017 trial for 2L cervical cancer
Completed
2
146
Europe, Japan, US, RoW
Bintrafusp alfa, M7824
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Uterine Cervical Neoplasms
04/22
12/22
NCT04396886: Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Completed
2
38
RoW
Bintrafusp Alfa
The University of Hong Kong, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Nasopharyngeal Carcinoma, Recurrent Carcinoma, Metastatic Cancer, Non-keratinizing Carinoma
09/22
07/23
NCT04491955: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Completed
2
32
US
CV301, MSB0011359C, N-803, NHS-IL12
National Cancer Institute (NCI)
Small Bowel Cancers, Colorectal Cancers
10/22
08/24
NCT04284332: Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)

Not yet recruiting
2
37
RoW
Bintrafusp alfa
The University of Hong Kong, Merck KGaA, Darmstadt, Germany
Nasopharyngeal Carcinoma, Immunotherapy, NPC
01/23
01/23
LUNG 005, NCT03840902 / 2018-003265-34: M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Jan 2024 - Mar 2024: Data from trial for unresectable stage III NSCLC
Terminated
2
153
Europe, Canada, Japan, US, RoW
M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
02/23
02/23
PEBBLE, NCT04878250 / 2020-004223-16: Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder

Not yet recruiting
2
49
NA
Bintrafusp alfa
Queen Mary University of London, Merck Healthcare KGaA
Transitional Cell Carcinoma, Bladder Cancer
07/23
01/25
TAPESTRY, NCT04595149: Tapestry: Addition of TGF-β and PDL-1 Inhibition to Definitive Chemoradiation in Esophageal Squamous Cell Carcinoma

Recruiting
2
52
Europe
Bintrafusp alfa, M7824
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Neoplasm, Esophagus, Malignant Esophagus Tumor, Neoplasm, Esophageal
11/23
11/28
MC1821, NCT04396535: Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Terminated
2
10
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate
Mayo Clinic, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/23
12/23
NCT04417660: Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

Recruiting
2
44
US
M7824
National Cancer Institute (NCI)
Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
12/24
01/25
NCT05145569: Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

Withdrawn
2
33
US
Carboplatin AUC 5 and paclitaxel, Carbo/Taxol, HCW9218
Haider Mahdi, HCW Biologics
Ovarian Cancer
05/26
01/28
NCT03315871: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Active, not recruiting
2
40
US
PROSTVAC-V, PROSTVAC-F, MSB0011359C (M7824), CV301
National Cancer Institute (NCI)
Prostate Cancer
01/25
01/25
NCT05012098: Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Active, not recruiting
2
11
US
Bintrafusp alfa / M7824
National Cancer Institute (NCI)
Olfactory Neuroblastoma, Esthesioneuroblastoma, Neoplasm of the Nasal Cavity
08/25
08/25
TRUST, NCT04874311: Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Recruiting
2
80
Europe
Bintrafusp alfa, Doxorubicin
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
09/24
03/25
NCT05445882: N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Withdrawn
2
28
US
Bintrafusp alfa, N-803, BN-Brachyury
National Cancer Institute (NCI)
Castration Resistant Prostate Cancer
04/24
04/24
BIMES, NCT05005429 / 2020-004902-67: Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma

Completed
2
47
Europe
Bintrafusp alfa, M7824
Fundación GECP
Mesothelioma; Lung
02/24
02/24
NCT03451773: M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Terminated
1/2
7
US
M7824, MSB0011359C, Gemcitabine, Gemzar
National Cancer Institute (NCI)
Cancer of Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
05/20
05/20
NCT04247282: Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Completed
1/2
21
US
M7824, bintrafusp alfa, N803, Anktiva, TriAd vaccine, ETBX-011, ETBX-051 & ETBX-061
National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Neoplasms
08/21
06/23
NCT04648826: Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Withdrawn
1/2
0
US
AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine
National Cancer Institute (NCI)
Sarcomas, Melanomas, Germ Cell Tumors, Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas), Pulmonary Metastases
12/21
12/21
NCT04327986: Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Terminated
1/2
3
US
M7824, bintrafusp alfa, M9241, NHS-IL12, SBRT, Stereotactic body radiotherapy
National Cancer Institute (NCI)
Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
01/22
02/22
NCT04287868: Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Active, not recruiting
1/2
51
US
PDS0101, M7824, MSB0011395C, NHS-IL12
National Cancer Institute (NCI)
Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
07/22
07/26
LUNG 024, NCT03840915 / 2018-004040-28: M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Hourglass Jan 2022 - Mar 2022 : Data from trial in combination with chemotherapy for 1L NSCLC
Completed
1/2
70
Europe, US
Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Bintrafusp alfa, Paclitaxel
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Carcinoma, Non-Small-Cell Lung
07/22
07/22
NCT04220775: Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

Terminated
1/2
3
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
10/22
10/22
20-C-0104, NCT04432597: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Active, not recruiting
1/2
39
US
PRGN-2009 (Phase I), PRGN-2009 (Phase II), M7824, MSB0011359C, MRI, Magnetic resonance imaging, Bone scan, CT scan, Computed tomography scan, Brain CT, Brain computed tomography, Brain MRI, Brain magnetic resonance imaging, Biopsy (Phase I), Biopsy (Phase II)
National Cancer Institute (NCI)
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer, Cervical Cancer
11/22
11/25
NCT04297748: Bioimaging Study of 89Zr-M7824 in NSCLC

Terminated
1/2
5
RoW
89Zirconium-M7824, M7824, bintrafusp alfa
Olivia Newton-John Cancer Research Institute, Merck Healthcare KGaA, Austin Health
Non-Small Cell Lung Cancer
11/22
11/22
NCT04574583: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Completed
1/2
12
US
SX-682, M7824, BinTrafusp Alfa, MVA-BN-CV301, modified vaccinia Ankara (MVA)-BN-CV301, recombinant fowlpox viral (FPV)-CV301
National Cancer Institute (NCI)
Metastatic Cancer, Solid Tumors
02/23
05/23
NCI-2018-00919, NCT03436563: M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

Active, not recruiting
1/2
74
US
Anti-PD-L1/TGFbetaRII Fusion Protein M7824, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Bintrafusp Alfa
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8
08/23
08/23
QuEST1, NCT03493945: Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat

Active, not recruiting
1/2
53
US
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat
National Cancer Institute (NCI)
Metastatic Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor
12/24
12/24
21-C-0001, NCT04633252: M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Recruiting
1/2
86
US
ADT, Prednisone, M7824, Docetaxel, M9241
National Cancer Institute (NCI)
Cancer Of Prostate, Prostate Neoplasms
12/24
12/24
NCT03554473: M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Recruiting
1/2
80
US
M7824, Topotecan, Temozolomide
National Cancer Institute (NCI)
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
01/27
01/27
NCT04708470: A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Recruiting
1/2
107
US
Bintrafusp Alfa, PDS01ADC, Entinostat
National Cancer Institute (NCI)
Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV, Anal Cancer, Cervical Cancer, Penile Cancer, Vulvar Cancer, Vaginal Cancer, Colon Cancer
12/25
12/26
NCT04835896: Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer

Completed
1/2
49
RoW
M7824+paclitaxel
Yonsei University
Recurrent/Metastatic Gastric Cancer
10/23
10/23
NCT04789668: Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Completed
1/2
8
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Pimasertib, AS703026, EMD 1036239, MSC1936369, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/23
12/23
NCT04303117: NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Recruiting
1/2
80
US
NHS-IL12, M7824
National Cancer Institute (NCI)
Kaposi Sarcoma
09/25
12/28

Download Options